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Abstract
This chapter will focus on the subject of tissue regeneration in a variety of different sur-
gical fields and operations. We will explore the use of acellular dermal matrices, stem 
cell-based therapies, gene regulation, emerging 3D printing techniques and their poten-
tial applications in surgery. Acellular dermal matrices (ADMs) are biological materials 
derived from human or animal tissue through complicated and expensive decellularisa-
tion processes, leading to acellular material that can be used to aid tissue healing. ADMs 
were first introduced for the treatment of burn injuries, but are now widely used in a 
variety of surgical fields, including abdominal wall and breast reconstruction. A wide 
range of materials can be used to produce ADMs, but usually include bovine, porcine or 
human tissues (e.g., dermis and pericardium). ADMs act as scaffolds onto which human 
tissue can incorporate, allowing for an innovative, yet a very effective way to aid tissue 
regeneration. Stem cell therapies also hold promise in aiding tissue regeneration in the 
coming years and we will also explore techniques that are currently being researched by 
prominent scientists all across the world. For example, adipose tissue-derived stem cells 
(ASCs) are a potentially revolutionary therapy in regenerative medicine. We will review 
the current evidence available and consider the possible clinical applications of ASCs, 
including their potential to treat ischaemic diseases and their role in healing chronic 
wounds. ASCs are adult stem cells, which display similar morphology and differentia-
tion properties to adult mesenchymal stem cells (MSCs). The multiple linage pathways 
displayed by ASCs allows a variety of tissues to be repaired and maintained. Moreover, 
adipose tissue is abundant, easily accessible and is able to be repeatedly harvested with 
low morbidity. Previously, autologous fat grafting was more commonly utilised for man-
aging volume defects in reconstructive and plastic surgery; however, recent literature has 
revealed promising therapeutic effects of ASCs in tissue regeneration. Finally, gene regu-
lation, which holds promise in musculoskeletal diseases, and 3D printed scaffolds that 
aid neural regeneration will also be discussed in this chapter as emerging, and potentially 
very promising, tissue regeneration techniques.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
Tissue regeneration is a vast subject, with many different important aspects to consider. From 
groundbreaking advances in the use of acellular dermal matrices, to the still-evolving stem 
cell treatments, this chapter provides an overview of the essentials in tissue regeneration sci-
ence. We will explore the use of acellular dermal matrices, stem cell-based therapies, gene 
regulation, emerging 3D printing techniques and their potential applications in surgery and 
provide an overview of wound and tissue healing in general.
2. Acellular dermal matrices
Acellular dermal matrices (ADMs) are biological materials derived from human or animal 
tissue through complicated and expensive decellularisation processes, leading to acellular 
material that can be used to aid tissue healing. ADMs were first introduced for the treatment 
of burn injuries, but are now widely used in a variety of surgical fields, including abdominal 
wall and breast reconstruction. A wide range of materials can be used to produce ADMs, but 
usually include bovine, porcine or human tissues (e.g., dermis, pericardium). ADMs act as 
scaffolds onto which human tissue can incorporate, allowing for an innovative, yet a very 
effective way to aid tissue regeneration (see Figure 1).
First introduced in 1994, a specific acellular dermal matrix (AlloDerm) was used as a dermal 
substitute in a full thickness burn injury [2]. This overcame the troubling consequences of 
significant scarring and contracture after the use of split-thickness autografts used for full 
thickness injuries. A high percentage of ‘take’ was seen and was assessed using histology and 
electron microscopy [2]. No specific immune response was seen and this is owing to the pro-
cesses in which the actual acellular dermal matrices are produced. In addition to the benefits 
of reduced scarring, contracture and avoidance of immune response, acellular dermal matri-
ces also ensured that any wound of the donor site was avoided—purely due to the fact that 
the donor site was not necessary! This was particularly important and useful in patients with 
extensive burns where the donor site availability was limited. All of this led to the increasing 
popularity of the use of acellular dermal matrices in the treatment of burns and, later on, the 
introduction of acellular dermal matrices into other surgical fields.
Complex engineering procedures are involved in producing acellular dermal matrices and 
will also depend on the original type of tissue used. Decellularisation is an essential process 
and ensures there is no immune reaction once the acellular dermal matrix is introduced into 
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Figure 1. Comparison of DermaMatrix to normal human skin (courtesy of Synthes® [1]).
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the recipient’s body. All donor cells and antigenic epitopes that have a potential to induce an 
immune response are removed using a variety of detergents (dependent on a particular type 
of acellular dermal matrix)—this essentially leaves a scaffold, consisting of collagen, growth 
factor receptors and vascular channels [3]. Dehydration of the matrix also allows for easier 
tissue handling and prolonged shelf life [4]. Certain acellular dermal matrices are also termi-
nally sterilised; however, there is no clear evidence whether this provides an advantage [5].
As mentioned above, a variety of different donor tissues can be used in the production of acel-
lular dermal matrices. Commonly, bovine, porcine or human tissues are used, with dermis 
and pericardium being the most usual types of tissue utilised. A variety of acellular dermal 
matrices exist at present, some more commonly used examples are listed in Table 1 [6]:
One of the authors (Chaturvedi) of this chapter has long experience of using the Veritas® acel-
lular dermal matrix, made from bovine pericardium, and has presented this experience in 
one of the largest series for breast reconstruction [12]. They have found that the advantages of 
Veritas® included the easy handling and reduction in the incidence of red breast syndrome, as 
compared to porcine allografts [12].
Acellular dermal matrices act as scaffolds for the recipients’ tissues to grow and revascularise 
upon [2]. Whilst providing nutritional and structural support, acellular dermal matrix inte-
grates into the surrounding tissues and is eventually replaced by functional autologous tissue 
(see Figure 2) [2].
Acellular dermal matrices are used widely in abdominal wall, burn and breast reconstruction. 
The management of burns with acellular dermal matrices has already been mentioned, with 
significant benefits of ADM over split thickness skin grafts in terms of donor site sparing, less 
contracture, scarring and avoidance of immune response. In addition to burns management, 
acellular dermal matrices were also initially used for tympanic membrane replacement, dural 
repairs, gingival grafting and, as already mentioned, abdominal wall repair. The use of acel-
lular dermal matrices in these areas gave a start to what is now an increasingly important and 
prevalent component of both reconstructive and aesthetic surgery.
Breast and plastic surgeons currently actively utilise acellular dermal matrices in a variety of 
procedures, in particular, implant-based breast reconstruction [5]. Acellular dermal matrices 
Name of acellular dermal matrix Type of acellular dermal matrix
FlexHD® (Ethicon, Somerville, NJ) [7] Donated human allograft skin
AlloDerm® (LifeCell, Branchburg, NJ) [8] Donated human allograft skin
Neoform™ (Mentor, Santa Barbara, CA) [9] Donated human allograft skin
DermaMatrix™ (Synthes, West Chester, PA) [1] Donated human allograft skin
Permacol™ (Covidien, Boulder, CO) [10] Porcine dermal implant
Strattice® (LifeCell, Branchburg, NJ) [11] Porcine dermal implant
Veritas (Baxter, Deerfield, IL) [12] Bovine pericardium
Table 1. Examples of currently available acellular dermal matrices.
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have been used in breast surgery since 2001, with many benefits gleaned from their use [5]. 
Acellular dermal matrices have allowed for immediate breast reconstruction with implants 
by avoiding the stage of tissue expanders. Mastectomy can be performed with immediate 
implant based, acellular dermal matrix reconstruction, allowing for immediate results and 
avoiding a second operation at a later date. Not only do acellular dermal matrices act as scaf-
folds for tissue regeneration in this case, but also add an additional layer of tissue protection 
for the foreign body, that is, the implant (see Figure 3) [13]. Other examples of applications 
of acellular dermal matrices in breast surgery include correction of symmastia, incorpo-
ration into the upper pole (to decrease surface rippling) and correction of inframammary 
fold malposition [5]. In addition, acellular dermal matrices are also used in two-stage breast 
reconstruction procedures with tissue expanders; however, despite advantages, such as faster 
expansion, improved lower pole projection and better aesthetic shape, the costs are high and 
need considered prior to individual patient use [5].
New ways of utilising acellular dermal matrices in breast surgery have also been trialled 
and include use of meshed and fenestrated acellular dermal matrices [14]. This allows for 
Figure 2. Patient X—Robust recellularisation and remnants of Strattice™ tissue matrix, 31 months post-implantation 
(courtesy of LifeCell [11]).
Figure 3. Tissue expander placement into the Pectoralis major and acellular dermal matrix pocket (courtesy of Weichman 
et al. [12]).
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the reduction of costs, with evidence also showing that with fenestrated acellular dermal 
matrices, the incidence of capsular contractures, infections and seroma formation can be 
decreased [5].
Complications associated with acellular dermal matrices depend on the type of the acellular 
dermal matrix used and also the particular procedure it is used for. Breast reconstruction with 
acellular dermal matrix can cause increased risk of post-operative infection, skin necrosis and 
post-operative seroma [15]. The correct patient should be identified in order to ensure the 
risks that are acceptable. Caution needs to be used with obese patients (BMI > 30), simultane-
ous axillary clearance and smoking history. Radiation will affect any reconstructed breast; 
however, acellular dermal matrices have, in fact, been shown to reducing the severity of cap-
sular contracture [15].
The use of acellular dermal matrices in abdominal wall reconstruction offers an alternative to a 
permanent prosthetic mesh and has been in use since mid 2000s [16]. Although some surgeons 
prefer acellular dermal matrices for abdominal wall reconstructions, concerns have previously 
been raised regarding the long-term outcomes of acellular dermal matrices as compared to 
synthetic meshes, with the main worry being the durability. A recent study, however, showed 
that hernia recurrence rates with acellular dermal matrices were comparable to those done 
with synthetic mesh—in particular, it was also seen that xenograft acellular dermal matrices 
led to even lower recurrence rates than human allografts [17]. The question of cost, however, 
arises again, and synthetic meshes are in fact cheaper than acellular dermal matrices [17].
Outcomes with acellular dermal matrices in breast surgery have already been mentioned (and 
there is extensive literature for this subject, including a systematic review), but favourable 
reports have been published on outcomes in pelvic, abdominal, chest wall reconstruction, 
dural repair, hand surgery, urethral reconstruction and gingival graft procedures, too [6]. 
Butler et al. successfully used AlloDerm in the reconstruction of large and complex pelvic, 
chest and abdominal wall defects [18]; however, further studies would be needed in the use of 
acellular dermal matrices for dural repair (Chaplin et al. successfully used XenoDerm in a por-
cine model and called it “a nearly ideal dural replacement”) [19]. Kim et al. also successfully 
used acellular dermal matrix for a recurrent first dorsal web space defect, showing excellent 
cosmetic and functional results [20]. Aichelmann-Reidy et al. showed that acellular dermal 
matrix could also be a useful substitute in root coverage procedures [21]. Controversies, 
however, still exist and some studies have shown increased infection rates with ADM-based 
reconstruction as compared to non-ADM-based reconstruction [22].
Significant costs are also involved when using acellular dermal matrices and remain a topi-
cal issue in all fields of surgery. Some situations where costs may be unacceptable have 
already been considered, for example, with some general surgeons preferencing synthetic 
meshes in abdominal wall reconstruction due to decreased costs [17]. However, in cases 
where acellular dermal matrix allows for a two-stage procedure (e.g., implant-based recon-
struction with tissue expanders placed during the primary procedure) to be converted into 
a single-stage procedure (i.e., implant-based ADM reconstruction without the need of tissue 
expanders), significant savings will be made and this needs to be considered on an indi-
vidual patient basis.
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3. Mesenchymal stem cells
The exciting field of stem cell therapies has rapidly evolved in order to provide a potential 
alternative treatment for tissue repair and to enable the regeneration of injured organs. New 
developments are continually arising from this promising topic of research.
Stem cells are unique in that they are undifferentiated cells that can renew themselves through-
out the entire lifespan of an organism. They develop from one common precursor and have 
the ability to differentiate into multiple cell types with specific functions (see Figure 4). Stem 
cells are characterised by their ability to self-renew over prolonged periods of time [23]. Stem 
cells that have the potential to repair surgical wounds include mesenchymal stem cells (MSC), 
embryonic stem cells (ESC) and induced pluripotent stem cells (iPS) [24].
The most commonly utilised stem cells are MSCs, which are derived from adult patients. 
Autologous mesenchymal stem cells are present in almost all adult tissues including the dermis, 
periosteum and adipose tissue, solid organs, such as the liver, lungs and spleen and within bone 
marrow and blood, including from the peripheries, menstruation and the umbilical cord [25].
There has been great enthusiasm within the literature regarding the potential use of stem 
cells in tissue regeneration over the last decade. The initial focus of research surrounded the 
clinical applications of embryonic stem cells. However, over the past decade, there has been a 
move within the scientific community to research the potential applications of mesenchymal 
Figure 4. Skeletal regeneration by mesenchymal stem cells: what else (courtesy of Andrades et al. [26]).
Scaffold Biomaterials in Tissue Regeneration in Surgery
http://dx.doi.org/10.5772/intechopen.73657
53
stem cells. In comparison to embryonic-derived stem cells, there are less ethical concerns sur-
rounding their cultivation and utilisation [27].
Traditionally MSCs were derived from adult bone marrow using a bone marrow aspirate. 
However, lately there has been mounting interested in harvesting MSCs from adipose tissue, 
these are known as adipose-derived stem cells (ASCs). ASCs are of value as they are abundant 
in supply and easily accessible by means of an excised solid block of tissue or through liposuc-
tion techniques [27]. The International Society for Cellular Therapy instituted the following 
criteria to identify human mesenchymal stem cells (hMSCs) (see Table 2) [28].
Adipose tissue is a highly complex tissue derived from mesodermal origin [28]. Its main func-
tions include energy storage, insulation, protection from mechanical injury, endocrine properties 
and now as a source of multipotent stem cells [29]. It can be classified as brown and white adi-
pose tissue. Thermogenic brown tissue is responsible for energy expenditure and is mostly found 
in the foetus and new born babies [29]. White adipose tissue is located subcutaneously and intra-
abdominally and is responsible for energy storage and insulation (Figure 5). White tissue tends 
to be in abundance and thus renders it a viable long-term option for supply of stem cells [25].
Additionally, subcutaneous adipose tissue can be classified as superficial or deep tissue. The 
differential potential of ASCs may be altered depending on the location of the harvest. Taranto 
et el. demonstrated varying stem cell properties within subcutaneous tissues dependant on 
their location. Adipose tissue yielded from superficial tissues demonstrated increased multipo-
tency [31]. One study has shown that ASCs derived from superficial tissues displayed a slightly 
higher osteogenic potential than from the deep layer [32]. Previous reports suggest that the 
yield of ASCs is 100–500 times higher in comparison to bone marrow-derived stem cells [30, 32].
Throughout the literature, there are a number of methods described for the cultivation of 
MSCs. Naderi et al. describes the isolation and cultivation techniques to obtain  ASCs [33]. 
The adipose tissue is chopped and digested by collagenase and centrifuged in the laboratory. 
Isolated stem cells are cultivated and subsequently differentiated into a variety of different 
cell lineages. During pre-clinical trials, ASCs have proven to be very stable under cell culture 
conditions with a normal haploid karyotype remaining following 100 duplications [34]. ASCs 
can successfully be cryopreserved whilst maintaining their viability therefore ASCs could be 
potentially stored prior to use [35].
An extensive volume of research investigating the role and mechanism of action of MSCs in 
wound healing has been undertaken. Motegi et al. and Fromm-Dornieden et al. recently sum-
marised this into two main categories [28, 34]. These include promoting wound healing through: 
(I) paracrine actions with nearby cells through the release of growth factors and cytokines and 
(II) differentiation of cells into resident cells to create a scaffolding to encourage healing. The 
1. Proliferation in vitro as plastic-adherent cells.
2. Positive expression of CD105, CD73, CD90 and negative expression of the haematopoietic cell surface markers 
CD45, CD34, and CD14, CD11b and CD79α, or CD19 and HLA-DR.
3. Differentiation into osteoblasts, adipocytes and chondrocytes in culture conditions in vitro.
Table 2. Adapted from ‘Mesenchymal stem cells: The roles and functions in cutaneous wound healing and tumour 
growth’ [27].
Tissue Regeneration54
paracrine mechanisms enable numerous growth factors to be secreted including basic fibro-
blast growth factor (bFGF), hepatocyte growth factor (HGF), keratinocytes growth factor (KGF), 
transforming growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF), which 
in turn promotes angiogenesis and therefore wound healing [29, 33]. These growth factors are 
thought to have anti-inflammatory actions, enhancing wound healing by dampening down 
inflammation at the wound site [29]. Macrophage recruitment is increased. Macrophages are 
classified as classically activated (M1) and alternatively activated (M2). M2 macrophages have 
an important role in the progression of wound healing and it is thought that MSCs increase 
macrophage polarisation in wounds and therefore enhance wound healing [36]. Endothelial 
cell recruitment is also increased [36]. MSCs have the ability to differentiate into the resident 
site-specific cells, including, fibroblasts, myofibroblasts, keratinocytes and pericytes [36].
Cells known as pericytes, with similar features to mesenchymal cells, have been discovered 
within the blood vessels in multiple organs. Crisan et al. described that certain perivascular cells 
isolated from various organs, including the skin, showed differentiation into multiple  lineages 
Figure 5. Distribution of brown and white adipose tissue within the human body (courtesy of Kocan et al. [29]).
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both in vitro and in vivo [37]. This research surmised that it is likely that blood vessel walls may 
hold a reserve of mesenchymal-like stem cells that are involved in the repair and neovasculari-
sation of wounds. However, the exact mechanisms and significance remains unknown.
Patient selection for harvesting is an important factor because biologic properties can be 
affected by systemic disease. Adipose tissue that is extracted from patients with diabetes is 
inferior to adipose tissue that has not been subjected to systemic disease. In tissue exposed to 
systemic illness, there is loss of cell differentiation ability, increased levels of failed division 
and apoptosis and an overall reduction in the levels of growth factors secreted [38].
There are few human clinical trials involving the applications of MSCs and even fewer eval-
uating the utilisation of adipose cells. The current use of ASCs in clinical practice remains 
limited to trials. A number of animal model studies have demonstrated the promising pos-
sibilities of adipose-derived stem cells and there are a number of small pilot clinical trials, 
which have been published in the literature recently with many new studies emerging fre-
quently. This exciting data gives promise to the potential clinical applications of ASCs and 
with new information continuing to evolve, the routine use of stem cells in clinical practice 
remains a tangible prospect in the near future. This section of the chapter provides up to date 
evidence and a summary of recent studies involving ASCs.
Nie et al. investigated the mechanisms of action of ASCs in wound healing [39]. ASCs were 
incorporated into full thickness excisional wounds in both diabetic and non-diabetic rats. The 
study showed that wound healing was accelerated and time taken to close wounds in both 
groups was shortened. There was increased re-epithelisation and advanced development of 
granulation tissue within the wound. Enhanced neovascularisation was also shown due to the 
increased secretion of angiogenic growth factors.
Park et al. recently investigated the role of allogenic ASCs in the treatment of complex perianal 
fistulas secondary to Crohn’s disease [40]. In this small pilot multicentre, clinical trial partici-
pants had complex non-healing perianal fistulas, which had not healed by conventional tech-
niques (surgery or infliximab treatment). The initial group of participants received a smaller 
dose of ASCs than the second group. At 6-month follow-up, 50% of participants had achieved 
complete closure of the fistula, which was maintained at the final follow-up at 8 months.
A phase one clinical trial demonstrated the effect of autologous-derived adipose stem cells 
in patients with severe peripheral arterial disease with chronic non-healing ulcer disease. 
All participants had non-vascularisable critical limb ischaemia with lower limb rest pain or 
ulcers and a low ankle systolic oxygen pressure. ASCs were injected intramuscularly into 
the ischaemic limb with no complications recorded. Most participants showed an increase in 
trans-cutaneous oxygen pressure and improved ulcer healing [41].
Kim et al. studied the effectiveness of stem cell treatment in patients with chronic non-healing 
wounds following complications of soft tissue nasal fillers [42]. ASCs were harvested from 
the patient’s subcutaneous adipose tissue. Following preparation in the laboratory, the adi-
pose cell containing solution was injected into the dermis and subcutaneous layer around the 
wound. All participants experienced enhanced wound healing and at 6 months post treatment 
all wound sizes were reduced. These results lead the authors to propose that stem cells could 
be considered in the future for routine use as a treatment of complications of filler injections.
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In addition to skin wound healing, there have been advances within the role of stem cells 
in orthopaedics. A recent study focused on the role ASCs in the repair of meniscal injuries. 
Toratani et al. created meniscal defects in rabbits and injected autologous stem cells from adi-
pose tissue into half of the subjects [43]. ASCs were found to promote meniscus healing in the 
rabbit model. This paper offers promise for future clinical uses as a potential new treatment 
for meniscal injuries subject to further studies.
Stem cells could potentially revolutionise the treatment of chronic heart disease. Atherosclerosis 
is the leading cause of morbidity and mortality in the developed world with risk factors includ-
ing diabetes, hypertension, smoking and obesity. Researchers have endeavoured to develop 
a stem cell-based therapy for the treatments of ischaemic heart disease and cardiac failure. 
Numerous preclinical studies have demonstrated promising therapeutic benefits using ASCs 
with the improvement in left ventricular function and reduction in infarct size [44]. However, 
these successful results have yet to be seen in human trials. The difference in results is thought 
to be due to the source of stem cells. In animal trials, MSCs were harvested from healthy 
donors; however, in comparison in the clinical trials, the stem cells were collected from the 
patient with known atherosclerotic disease and potentially other serious co-morbidities [45]. 
Further research in this field continues to evolve to in order to create a successful therapy.
4. Gene regulation
Other novel tissue regeneration methods have been trialled in both animal and human 
studies. For example, genetics is an ever-evolving field when it comes to finding ways and 
methods of aiding tissue regeneration. Animal studies provide a starting point for future 
discoveries—for example, Kang et al. investigated tissue regeneration enhancer elements 
(TREEs), providing evidence that these elements trigger gene expression in injury sites [46]. 
The authors of this particular study felt that these findings could further be extrapolate in 
the future to assess their regenerative potential in vertebrate organs [46]. Gene regulation 
to aid tissue regeneration has been investigated in human studies, too. Recent studies by 
Finkel et al. and Mendell et al. showed promise in motor neurone diseases, specifically spi-
nal muscular atrophy [47, 48]. Finkel et al. modified promoted increased production of the 
survival motor neurone (SMN) protein with an antisense oligonucleotide drug and showed 
that infants with spinal muscular atrophy receiving this drug were more likely to be alive 
and have improved motor function that the control group [47]. Patients in the Mendell et al. 
study received adeno-associated viral vector infusion containing DNA coding for SMN; 
these patients again, survived longer, achieved motor milestones better and had improved 
motor function than historical cohorts [48]. Musculoskeletal tissue regeneration is a great 
challenge for scientists and lots of studies have looked into potential options, in addi-
tion to the two mentioned already. Padilla et al. discuss a variety of techniques, including 
blood derived biological drug delivery therapies, which have significant potential for tis-
sue regeneration [49]. For example, platelets release hepatocyte growth factor and stromal 
cell-derived growth factor 1, both known to be involved in wound healing and prolifera-
tion [49]. There is a significant need for further randomised trials and systematic reviews 
to assess if these therapies could be used routinely for the treatment of  musculoskeletal 
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 conditions. These are just examples of how gene regulation can lead to significant changes 
in tissue regeneration and improved clinical outcomes; and future research will be needed 
to assess safety of such gene therapies for widespread use.
5. 3D printing
In addition to novel gene regulation techniques, there have also been advancements made 
in the promising area of three-dimensional (3D) printing for medical needs. 3D printing has 
revolutionised many aspects of our lives, with its uses and benefits still being tested in medi-
cine. 3D printing has the potential to revolutionise the way we practice medicine and tissue 
regeneration and transplantation are two fields where opportunities are endless. It is a well-
known fact that the need and demand for organ and tissue replacement largely outweighs 
the supply, even with recently increasing numbers of deceased donors [50]. What if we could 
eliminate the need for donors and, at the same time, resolve a major issue associated with 
Figure 6. Bone scaffolds generated by selective laser sintering, (A) image of the scaffold, (B) front view, (C) top view and 
(D) back view of bone scaffold parts, courtesy of Do et al. [50].
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organ transplantation – the risk of immune rejection? Do et al. speaks about this in an article 
about 3D printed scaffolds and their potential applications [51]. The aim would be to create 
scaffolds that have properties of the native recipient microenvironment and the ability to pro-
mote angiogenesis and osteogenesis, and various tissue engineering techniques could be used 
in order to facilitate this process and this is still a work in progress, albeit an ever-expanding 
and promising field (see Figure 6). Other studies have suggested that 3D scaffolds could also 
exhibit bactericidal properties, and aid not only tissue regeneration, but also prevent the high 
risk of infection that comes with any foreign body or implant. Correiaa et al. have shown that 
silver nanoparticles could be a suitable way to achieve this [52]. The idea of 3D printing has 
attracted neuroscientists, too, and Zhu et al. hypothesised that the combination of 3D printed 
scaffolding and low-level light therapy could aid neural regeneration, and favourable results 
have been achieved in this in vitro neural stem cell study [53]. Further studies will be needed 
to assess how effective and useful the proposed 3D printing methods for tissue regeneration 
in humans will actually be.
6. Conclusion
This comprehensive chapter summarised the subject of tissue regeneration in a variety of 
different fields of surgery. We explored the use of acellular dermal matrices in plastic and 
reconstructive surgery (e.g., for treatment of burns), breast surgery (e.g., for immediate breast 
reconstruction after mastectomy) and general surgery (e.g., abdominal wall repair). Stem cell-
based therapies were also discussed to reflect the promise they hold in aiding tissue regeneration 
in the coming years. Particular focus was placed on adipose tissue-derived stem cells and adult 
mesenchymal stem cells, both of which are a potentially revolutionary therapy in regenerative 
medicine. Finally, we discussed potential future benefits of using three-dimensional printed 
scaffolds and gene regulation—both of these fields are currently being investigated by scientists 
across the world to discover how best to adapt these techniques in day-to-day clinical practice.
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